INDBInternet News Database 2.5 Updated just now · 393 sources Show or hide images Light or dark

Mixed Topline Phase 3 Results for PDE5 Inhibitor in Early AD

Save Like Comments Compare coverage

Summary

Treatment with an investigational PDE5 inhibitor significantly slows clinical decline in patients with early AD not taking standard AD medications, but overall trial results are mixed.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Mixed Topline Phase 3 Results for PDE5 Inhibitor in Early AD

    Treatment with an investigational PDE5 inhibitor significantly slows clinical decline in patients with early AD not taking standard AD medications, but overall trial results are mixed.

Comments

Comments need JavaScript.